


UM6P Ventures invests in Infiuss Health to improve clinical trial participation and health equity in Africa

Democratizes access to clinical research in Africa by diversifying participant cohorts and shortening drug development timelines

CASABLANCA, MOROCCO, September 29, 2022 /EINPresswire.com/ -- Today, UM6P Ventures announced its investment in Infiuss Health. The startup is developing a decentralized SaaS platform to power remote research and clinical trials in Africa.



Pharmacological companies attempt to include a large and varied population within their phased trial cohorts to prove out their medical thesis. However, Africans, a significant group of genetically diverse participants, are not traditionally well represented within their demographic profile, rendering their trial outcomes potentially skewed.

There is a need for researchers to select a wider range of people from different demographics to participate in clinical research to reduce bias, promote health equity, and produce innovative scientific findings.

To date, Africa's participation is only a small percentage of the global clinical trials landscape, as a result of the regulatory and ethical implications of clinical trials. To that end, several individual regulatory bodies have joined efforts to ensure that clinical trials in African countries are conducted in accordance with international best clinical practices and ethical standards. Thus, with new regulatory structures in place in Africa, medicinal effectiveness and availability will be improved. In fact, Infiuss Health only services sponsors that have previously been approved by the U.S. FDA, which ensures that trials comply with the exacting framework required by U.S. regulations.

Infiuss Health provides clinical trial access to African participants and allows pharmaceutical companies to conduct and monitor these trials via the Infiuss Health Probe Platform. Through their direct-to-participant approach, they help corporate and academic researchers diversify

their cohorts by connecting them directly to thousands of eligible African participants to take part in their clinical studies.

"Our main mission is to make clinical research accessible to all Africans. We're very pleased to have UM6P Ventures' support as Infiuss Health continues to grow African clinical trials that will have enormous benefits, including improved healthcare and patient outcomes.", stated Melissa Bime, CEO and Founder of Infiuss Health.

Through a single dashboard, the all-in-one software platform helps companies identify and select the right sites for trials, manage the entire research process, remotely recruit participants, collect remote consent, gather, and analyze data and provide virtual support faster and cheaper than third-party contract research organizations.

"The clinical trial phase is decisive in the pharmacological development lifecycle. This is a branch of our Healthtech investment thesis that we have been actively investigating. The Infiuss Health team brings a solution, expertise, and experience that adds critical elements to our health science and technology ecosystem. We are confident in their ability to deliver on their value proposition and contribute to the improvement of the health system in Africa.", said Yasser Biaz, CEO of UM6P Ventures.

About UM6P Ventures

UM6P Ventures is the investment arm of UM6P, founded as a vehicle for the university to advance entrepreneurship and accelerate scientific innovation in Morocco and Africa, backed by the OCP Group. It is a seed-stage ventures firm that caters to innovators and entrepreneurs in the fields of science and technology and invests in startups from their creation to Series A funding.

UM6P Ventures provides early ventures with advanced infrastructure, platforms, talent, and programs native to UM6P. It builds explicit pathways to transition incubated or demonstrator projects to investable assets and brokers subsequent funding in capital markets.

In partnership with its ecosystem network of programs including incubators and accelerators and investors such as business angels and venture capital, UM6P Ventures provides an unmatched ability to fund, build and accelerate assets out of projects. UM6P Ventures has a robust ecosystem and an investment portfolio actively invested in Agrobioscience, Healthtech, Energy, Artificial Intelligence (AI), and Industry 4.0.

About Infiuss Health

Infiuss Health is a Clinical trial Management platform designed to power remote, hybrid, and onsite clinical trials in Africa, home of one of the most diverse populations in the world. The platform connects researchers and pharmaceutical companies and researchers directly to patients and participants. Africa, along with end-to-end clinical trial support. Our goal is to accelerate clinical drug development by leveraging technology got to connect more diverse

participants to research in order to deliver more effective therapies to patients.

Through our platform, hundreds of patents in Africa can access more clinical trial options that would otherwise not been accessible. On the other side, researchers can connect to a diverse population that has historically been difficult to reach. The platform is already being utilized by pharmaceutical companies and health organizations to recruit participants in 6 countries across Africa.

Public Relations Contacts

Infiuss Health Bekah Myers +1 9389003666 bekah@infiuss.com Kaoutar Sellami UM6P Ventures +212 662-377896 kaoutar.sellami@um6pventures.com Visit us on social media: Facebook Twitter LinkedIn Other

This press release can be viewed online at: https://www.einpresswire.com/article/593255042

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.